Heron Therapeutics Files 8-K for Material Agreement

TL;DR

HRTX signed a big deal on 8/22, filed 8-K on 8/28. Details TBD.

AI Summary

Heron Therapeutics, Inc. (HRTX) filed an 8-K on August 28, 2025, reporting a material definitive agreement entered into on August 22, 2025. The filing also includes financial statements and exhibits related to this agreement. Specific details of the agreement, including parties involved and financial implications, are not fully disclosed in the provided text.

Why It Matters

This filing indicates a significant new development or contract for Heron Therapeutics, which could impact its business operations, financial performance, and future strategic direction.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant financial or operational implications, but the lack of specific details in the provided text necessitates a medium risk assessment.

Key Players & Entities

• Heron Therapeutics, Inc. (company) — Registrant
• August 22, 2025 (date) — Date of earliest event reported
• August 28, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• 94-2875566 (ein) — I.R.S. Employer Identification No.
• 100 Regency Forest Drive , Suite 300 , Cary , NC 27518 (address) — Address of principal executive offices
• 858-251-4400 (phone) — Registrant's telephone number

FAQ

From the Filing

0000950170-25-112048.txt : 20250828 0000950170-25-112048.hdr.sgml : 20250828 20250828170214 ACCESSION NUMBER: 0000950170-25-112048 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20250822 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250828 DATE AS OF CHANGE: 20250828 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HERON THERAPEUTICS, INC. /DE/ CENTRAL INDEX KEY: 0000818033 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 942875566 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33221 FILM NUMBER: 251274494 BUSINESS ADDRESS: STREET 1: 4242 CAMPUS POINT COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582514400 MAIL ADDRESS: STREET 1: 4242 CAMPUS POINT COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: AP PHARMA INC /DE/ DATE OF NAME CHANGE: 20010511 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED POLYMER SYSTEMS INC /DE/ DATE OF NAME CHANGE: 19920703 8-K 1 hrtx-20250822.htm 8-K 8-K 0000818033 false 0000818033 2025-08-22 2025-08-22   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2025 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 100 Regency Forest Drive , Suite 300 , Cary , NC 27518 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code (858) 251-4400 N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share HRTX The Nasdaq  Capital Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐     Item 1.01 Entry Into a Material Definitive Agreement. Heron Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into an Office Lease Agreement (the “ Lease ”), dated as of August 22, 2025, with USEF HCG Fenton LLC, a Delaware limited liability company (the “ Landlord ”). The Lease is for the Company’s new corporate headquarters, which is approximately 16,837 rentable square feet (the “ Premises ”) at 25 Fenton Main Street, Cary, North Carolina, 27511 (the “ Building ”).   The Lease provides for a term of approximately one hundred eleven mon